Clinical and Economic Aspects of KRAS Mutational Status as Predictor for Epidermal Growth Factor Receptor Inhibitor Therapy in Metastatic Colorectal Cancer Patients

Publisher： Karger

E-ISSN： 1423-0232|81|5-6|359-364

ISSN： 0030-2414

Source： Oncology, Vol.81, Iss.5-6, 2012-01, pp. : 359-364

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Relationships of Insulin-Like Growth Factor-1 Receptor and Epidermal Growth Factor Receptor Expression to Clinical Outcomes in Patients with Colorectal Cancer

By  

Oncology, Vol. 76, Iss. 1, 2008-11 ,pp. : 42-48

Karger

Access to resources Recommend Favorite

Efficacy of Second-Line Bevacizumab-Containing Chemotherapy for Patients with Metastatic Colorectal Cancer following First-Line Treatment with an Anti-Epidermal Growth Factor Receptor Antibody

By  

Oncology, Vol. 92, Iss. 4, 2017-02 ,pp. : 205-212

Karger

Access to resources Recommend Favorite

Reply to colorectal carcinomas, KRAS p.G13D mutant allele–specific imbalance, and anti–epidermal growth factor receptor therapy

By  

CANCER, Vol. 119, Iss. 24, 2013-12 ,pp. : 4366-4367

John Wiley & Sons Inc

Access to resources Recommend Favorite

Colorectal carcinomas, KRAS p.G13D mutant allele–specific imbalance, and anti–epidermal growth factor receptor therapy

By  

CANCER, Vol. 119, Iss. 24, 2013-12 ,pp. : 4366-4366

John Wiley & Sons Inc

Access to resources Recommend Favorite

Mutational analysis and clinical correlation of metastatic colorectal cancer

By  

CANCER, Vol. 120, Iss. 10, 2014-05 ,pp. : 1482-1490

John Wiley & Sons Inc

Access to resources Recommend Favorite